semaglutide
Semaglutide Exclusion Cuts Pharmacy Profit By 47%
Semaglutide’s removal from the FDA’s 503B bulks list is expected to cut pharmacy profit on the drug by about 47 percent. The change forces compounding pharmacies to source the peptide from a smaller pool of suppliers, raising acquisition costs and extending delivery windows. Medical Disclaimer: This article is